Honigman Advises Carmot Therapeutics on Certain Patent Matters Related to Definitive Merger Agreement with Roche

Carmot Therapeutics, Inc. (Carmot), a clinical-stage biotechnology company dedicated to developing life-changing therapeutics for people living with metabolic diseases including obesity and diabetes, recently announced that it has entered into a definitive merger agreement for Roche to acquire Carmot at a purchase price of $2.7 billion upfront and the potential for $400 million in milestone payments. Honigman advised Carmot on certain patent strategy matters related to the merger as well as a potential initial public offering.

Read the transaction press release

The Honigman team that advised Carmot on patent strategy matters included IP partners Jonathan P. O’Brien, Ph.D., Heidi Berven, Ph.D., Harold Fox, Ph.D., Li Gao, Ph.D.